Literature DB >> 19526568

No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism.

Glenda Halliday1, Maria Trinidad Herrero, Karen Murphy, Heather McCann, Francisco Ros-Bernal, Carlos Barcia, Hideo Mori, Francisco J Blesa, José A Obeso.   

Abstract

The recent knowledge that 10 years after transplantation surviving human fetal neurons adopt the histopathology of Parkinson's disease suggests that Lewy body formation takes a decade to achieve. To determine whether similar histopathology occurs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-primate models over a similar timeframe, the brains of two adult monkeys made parkinsonian in their youth with intermittent injections of MPTP were studied. Despite substantial nigral degeneration and increased alpha-synuclein immunoreactivity within surviving neurons, there was no evidence of Lewy body formation. This suggests that MPTP-induced oxidative stress and inflammation per se are not sufficient for Lewy body formation, or Lewy bodies are human specific. Copyright 2009 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19526568     DOI: 10.1002/mds.22481

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  28 in total

1.  Behavioral phenotypes associated with MPTP induction of partial lesions in common marmosets (Callithrix jacchus).

Authors:  Kimberley A Phillips; Corinna N Ross; Jennifer Spross; Catherine J Cheng; Alyssa Izquierdo; K C Biju; Cang Chen; Senlin Li; Suzette D Tardif
Journal:  Behav Brain Res       Date:  2017-02-17       Impact factor: 3.332

Review 2.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

3.  shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

Authors:  Alevtina D Zharikov; Jason R Cannon; Victor Tapias; Qing Bai; Max P Horowitz; Vipul Shah; Amina El Ayadi; Teresa G Hastings; J Timothy Greenamyre; Edward A Burton
Journal:  J Clin Invest       Date:  2015-06-15       Impact factor: 14.808

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

5.  MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.

Authors:  Eduard R Mingazov; Gulnara R Khakimova; Elena A Kozina; Alexei E Medvedev; Olga A Buneeva; Ara S Bazyan; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

Review 6.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

Review 7.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

Review 9.  α-Synuclein and nonhuman primate models of Parkinson's disease.

Authors:  Scott C Vermilyea; Marina E Emborg
Journal:  J Neurosci Methods       Date:  2015-08-03       Impact factor: 2.390

10.  Nonhuman Primate Models of Neurodegenerative Disorders.

Authors:  Marina E Emborg
Journal:  ILAR J       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.